Wang Yan, Yao Lu, Liu Yi-qang, Xu Ye, Ou Yang-tao, Li Jin-feng, Wang Tian-feng, Fan Zhao-qing, Fan Tie, Lin Ben-yao, Xie Yun-tao
Breast Center, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China.
Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):511-4.
To investigate the prognostic significance of Her-2 expression in node-positive and node-negative breast cancer in Chinese women.
The Her-2 expression in breast cancers from 981 patients was detected by immunohistochemistry with anti-Her-2 (CB11) monoclonal antibody. The survival curves were analyzed by Kaplan-Meier method, and Cox regression model was applied to determine whether this factor is an independent predictor of survival in multivariate analysis.
Nineteen point seven percent of the patients showed positive Her-2 expression in their tumors. Patients with Her-2-positive tumors tended to be younger. The high level Her-2 expression was significantly associated with negative estrogen receptor and progesterone receptor status in their tumors (P < 0.05). Among 387 patients with node-positive disease, the 5-year disease-free survival (DFS) rate and 5-year overall survival (OS) rate were significantly lower in patients with Her-2-positive tumors than in patients with Her-2-negative tumors (DFS: 48.8% vs. 66.9%, P = 0.009; OS: 55.2% vs. 76.4%, P = 0.001), and Her-2 expression was an independent unfavorable prognostic factor for OS, but not for DFS in patients with node-positive disease. Among 591 patients with node-negative disease, Her-2 expression was not significantly associated with DFS and OS (P > 0.05).
Her-2 expression is an important prognostic factor in patients with node-positive disease, but not for patients with node-negative disease in Chinese women.
探讨Her-2表达在中国女性淋巴结阳性和阴性乳腺癌中的预后意义。
采用抗Her-2(CB11)单克隆抗体免疫组化法检测981例患者乳腺癌组织中的Her-2表达。采用Kaplan-Meier法分析生存曲线,并应用Cox回归模型在多因素分析中确定该因素是否为生存的独立预测因子。
19.7%的患者肿瘤组织中Her-2表达呈阳性。Her-2阳性肿瘤患者往往更年轻。肿瘤组织中Her-2高表达与雌激素受体和孕激素受体阴性状态显著相关(P<0.05)。在387例淋巴结阳性患者中,Her-2阳性肿瘤患者的5年无病生存率(DFS)和5年总生存率(OS)显著低于Her-2阴性肿瘤患者(DFS:48.8%对66.9%,P=0.009;OS:55.2%对76.4%,P=0.001),且Her-2表达是淋巴结阳性患者OS的独立不良预后因素,但不是DFS的独立不良预后因素。在591例淋巴结阴性患者中,Her-2表达与DFS和OS均无显著相关性(P>0.05)。
Her-2表达是中国女性淋巴结阳性患者的重要预后因素,但不是淋巴结阴性患者的重要预后因素。